GT 16239
Latest Information Update: 03 Jan 2001
Price :
$50 *
At a glance
- Originator GelTex Pharmaceuticals
- Class Antihyperlipidaemics
- Mechanism of Action Bile acid binding protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 03 Jan 2001 Discontinued-Preclinical for Hypercholesterolaemia in USA (PO)
- 21 Dec 2000 GelTex Pharmaceuticals has been acquired by Genzyme Corporation
- 24 Feb 1999 Preclinical development for Hypercholesterolaemia in USA (PO)